-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Saturday, Agenus Says 25% Of Recurrent Ovarian Cancer Patients Treated With BOT+BAL Were Alive And Off All Therapy At Last Follow-Up, With 48% Estimated Three-Year Survival Among Evaluable Patients

Benzinga·10/05/2026 06:57:38
Listen to the news
  • Survival estimate remained at 48% between years two and three, extending evidence of durable benefit
  • Results observed in heavily pretreated, difficult-to-treat population that received a median of four prior lines of therapy; nearly three-quarters of patients had platinum-resistant or refractory cancer